title: [Diagnosis and treatment of polycythaemia vera: state of the art].
abstract: Polycythaemia vera (PV), a condition characterized by blood hyperviscosity due to the expansion of the erythrocyte mass is the most common entity among all Philadelphia chromosome-negative myeloproliferative neoplasms. Arterial and venous thrombotic events are leading determinants of morbidity and mortality but impairment of quality of life due to vasomotor symptoms (erythromelalgia, pruritus) and disease-associated symptoms (tiredness, fatigue, pruritus, night sweats, vision problems, headache, concentration loss, abdominal discomfort, early satiety, fever, weight loss) are also present. The review of polycythaemia vera is actual as the updated WHO 2016 classification of myeloid neoplasms has changed the diagnostic criteria and a new second-line treatment option - JAK1/JAK2 inhibitor ruxolitinib - has been approved for patients who had an inadequate response to or are intolerant of hydroxyurea, which represents a breakthrough in the treatment of this patient population. Orv. Hetil., 2016, 157(44), 1743-1751.
authors: II. Belgyógyászati Klinika és Kardiológiai Központ, Haematológiai Osztály, Szegedi Tudományegyetem, Általános Orvostudományi Kar Szeged, Semmelweis u. 8., 6725.|Transzfuziológiai Tanszék, Szegedi Tudományegyetem, Általános Orvostudományi Kar Szeged.
authors: Imelda
authors: I
authors: Marton
authors: Hematológiai Tanszék, Debreceni Egyetem, Általános Orvostudományi Kar Debrecen.
authors: Zsófia
authors: Z
authors: Simon
authors: II. Belgyógyászati Klinika és Kardiológiai Központ, Haematológiai Osztály, Szegedi Tudományegyetem, Általános Orvostudományi Kar Szeged, Semmelweis u. 8., 6725.
authors: Zita
authors: Z
authors: Borbényi
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage; D019317:Evidence-Based Medicine; D006801:Humans; D009570:Nitriles; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D011087:Polycythemia Vera / Q000145:classification* / Q000175:diagnosis* / Q000188:drug therapy; D011720:Pyrazoles / Q000008:administration & dosage; D011743:Pyrimidines
chemical_list: D000925:Anticoagulants; D009570:Nitriles; D010975:Platelet Aggregation Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib
keywords: JAK1/JAK2 gátló ruxolitinib; JAK1/JAK2 inhibitor; Philadelphia-negative myeloproliferative neoplasms; Philadelphia-negatív myeloproliferativ betegség; WHO 2016; WHO 2016 classification; polycythaemia vera; ruxolitinib